Taigen Biopharmaceuticals Holdings Ltd
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic… Read more
Taigen Biopharmaceuticals Holdings Ltd (4157) - Total Assets
Latest total assets as of September 2025: NT$1.01 Billion TWD
Based on the latest financial reports, Taigen Biopharmaceuticals Holdings Ltd (4157) holds total assets worth NT$1.01 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Taigen Biopharmaceuticals Holdings Ltd - Total Assets Trend (2010–2024)
This chart illustrates how Taigen Biopharmaceuticals Holdings Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Taigen Biopharmaceuticals Holdings Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Taigen Biopharmaceuticals Holdings Ltd's total assets of NT$1.01 Billion consist of 92.5% current assets and 7.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 6.3% |
| Accounts Receivable | NT$7.33 Million | 0.6% |
| Inventory | NT$42.71 Million | 3.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Taigen Biopharmaceuticals Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Taigen Biopharmaceuticals Holdings Ltd's current assets represent 92.5% of total assets in 2024, an increase from 82.9% in 2010.
- Cash Position: Cash and equivalents constituted 6.3% of total assets in 2024, down from 77.9% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 15.0% in 2010.
- Asset Diversification: The largest asset category is inventory at 3.6% of total assets.
Taigen Biopharmaceuticals Holdings Ltd Competitors by Total Assets
Key competitors of Taigen Biopharmaceuticals Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Taigen Biopharmaceuticals Holdings Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Taigen Biopharmaceuticals Holdings Ltd generates 0.13x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Taigen Biopharmaceuticals Holdings Ltd is currently not profitable relative to its asset base.
Taigen Biopharmaceuticals Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.79 | 19.30 | 4.13 |
| Quick Ratio | 10.17 | 18.47 | 3.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$856.42 Million | NT$ 1.07 Billion | NT$ 296.69 Million |
Taigen Biopharmaceuticals Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Taigen Biopharmaceuticals Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.73 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -4.5% |
| Total Assets | NT$1.17 Billion |
| Market Capitalization | $145.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Taigen Biopharmaceuticals Holdings Ltd's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Taigen Biopharmaceuticals Holdings Ltd's assets decreased by 4.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Taigen Biopharmaceuticals Holdings Ltd (2010–2024)
The table below shows the annual total assets of Taigen Biopharmaceuticals Holdings Ltd from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.17 Billion | -4.52% |
| 2023-12-31 | NT$1.23 Billion | +17.46% |
| 2022-12-31 | NT$1.05 Billion | -24.83% |
| 2021-12-31 | NT$1.39 Billion | +150.30% |
| 2020-12-31 | NT$556.45 Million | -41.19% |
| 2019-12-31 | NT$946.11 Million | -20.34% |
| 2018-12-31 | NT$1.19 Billion | -21.97% |
| 2017-12-31 | NT$1.52 Billion | +84.85% |
| 2016-12-31 | NT$823.45 Million | +31.65% |
| 2015-12-31 | NT$625.46 Million | -43.05% |
| 2014-12-31 | NT$1.10 Billion | +125.74% |
| 2013-12-31 | NT$486.49 Million | -33.72% |
| 2012-12-31 | NT$733.95 Million | +20.22% |
| 2011-12-31 | NT$610.52 Million | -45.15% |
| 2010-12-31 | NT$1.11 Billion | -- |